Unknown

Dataset Information

0

Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab.


ABSTRACT:

Purpose

The tumor-infiltrating lymphocytes (TILs) expression in breast cancer is a positive prognostic marker for certain breast cancer subtypes. We evaluated the efficacy of dual anti-human epidermal growth factor receptor 2 (HER2) blockade in HER2-positive breast cancer and hypothesized that high TILs tumors are associated with better outcomes.

Methods

A total of 176 patients who were treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) between December 2015 and December 2018 were reviewed. They were grouped based on a cut-off value of the stromal TILs grade (≤ 20% TILs, > 20% TILs).

Results

In total, 107 patients (60.8%) achieved pathological complete response (pCR). Hormone receptor (HR)-negativity (p = 0.001) and a high TILs grade (p = 0.022) were independent predictors of pCR. Among the HR-negative patients, high TILs tumors were significantly associated with pCR (p = 0.035).

Conclusion

HR status and the TILs grade are significantly correlated with pCR in dual anti-HER2 neoadjuvant therapy. The evaluation of the TILs at baseline may be beneficial for predicting pCR in HER2-positive breast cancer.

SUBMITTER: Ha JY 

PROVIDER: S-EPMC8410619 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab.

Ha Joo Young JY   Kim Jeong Eun JE   Lee Hee Jin HJ   Jeong Jae Ho JH   Ahn Jin-Hee JH   Jung Kyung Hae KH   Gong Gyungyub G   Chae Eun Young EY   Kim Hak Hee HH   Chung Il Yong IY   Ko Beom Seok BS   Kim Sung-Bae SB  

Journal of breast cancer 20210709 4


<h4>Purpose</h4>The tumor-infiltrating lymphocytes (TILs) expression in breast cancer is a positive prognostic marker for certain breast cancer subtypes. We evaluated the efficacy of dual anti-human epidermal growth factor receptor 2 (HER2) blockade in HER2-positive breast cancer and hypothesized that high TILs tumors are associated with better outcomes.<h4>Methods</h4>A total of 176 patients who were treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) between Dec  ...[more]

Similar Datasets

| S-EPMC5299741 | biostudies-literature
| S-EPMC6335115 | biostudies-literature
2018-04-01 | GSE109710 | GEO
| S-EPMC10654605 | biostudies-literature
| S-EPMC11230995 | biostudies-literature
| S-EPMC7031180 | biostudies-literature
| S-EPMC9582484 | biostudies-literature
| S-EPMC5584549 | biostudies-literature
| S-EPMC8227457 | biostudies-literature
| S-EPMC5477653 | biostudies-literature